Analysis of semaglutide and NAION in the FDA adverse event database provides additional pharmacovigilance data on this potential eye safety signal.
Key findingAnalysis of semaglutide and NAION in the FDA adverse event database provides additional pharmacovigi
What the researchers found
Analysis of semaglutide and NAION in the FDA adverse event database provides additional pharmacovigilance data on this potential eye safety signal.
Why it matters
Relevant to peptide therapeutics.
How the study worked
In publication.
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Semaglutide: Nonarteritic Anterior Ischemic Optic Neuropathy in the FDA adverse event reporting system - A disproportionality analysis.
Obesity research & clinical practice, 19(1), 77-79
Citation
Azab, Marina; Pasina, Luca. (2025). Semaglutide: Nonarteritic Anterior Ischemic Optic Neuropathy in the FDA adverse event reporting system - A disproportionality analysis.. Obesity research & clinical practice, 19(1), 77-79. https://doi.org/10.1016/j.orcp.2025.01.011